11 © 2009 PerkinElmer© 2009 PerkinElmer© 2009 PerkinElmer© 2010 PerkinElmer
Kevin Hrusovsky, President,Life Sciences & Technology June 18th 2012
Revolutionizing Health though a Bioeconomy
9th Annual Community College Program Day
22
United Purpose
Innovate disruptive technologies that enable early detection, next generation treatment and disease prevention while optimizing health at an individual level to eradicate disease and sustain earth’s ecosystem.
33 Revolutionizing Global Health
Agenda
1
2 Catalyzing a Bioeconomy
State of Health
5
3 Disruptive Technology Enabling Personalized Health
44
Life Expectancy is Slowing
First time in 200 years, children’s life expectancy is shorter than parents
Gains are Plateauing
55 Source: NEJM, 2005; AHRQ, 2006; CBO, 2008; CDC, 2009
Transporting 100 People
Car Bus Bicycle
http://www.howwedrive.com/2010/06/
Life Expectancy is Inversely Correlated w/ Energy Use
66
While Healthcare may be Sick, There’s a Clear Path to 130
77
$Bill
ions
But…-5% consume 50-65+ spend 4x more
Extending Life (77 to 84) with Today’s Medicine Double Costs
88
~~
$2.5M
A Revolution in Medicine is Needed to Extend Life Economically
Expand life from 77 to 100 years with Asymptomatic Medicine
99
Two out of Three Adults and Kids are Overweight
CDC - childhood diabetes & prediabetes has mushroomed from 9% in ’90 to 23% in ‘08
Costs quadrupling; $400B (NEJM, 2005; AHRQ, 2006; CBO, 2008; CDC, 2009)
1010
Sugar Content of Common Foods
Disney: Quit junk food ads
NYC Mayor Bloomberg:Large Soda not a Right
Michelle Obama: End Obesity
1111
Earth4.5B years old
Life2B years old
Industrial Revolution; 11:59:59 on Dec 31
Humans150,000 years old
1800
1B
Population Growth Assaulting Ecosystems - Earth is Fighting Back!
1212
Earth4.5B years old
Life2B years old
Industrial Revolution; 11:59:59 on Dec 31
Humans150,000 years old
1800 1930
1B
2B
Population Growth Assaulting Ecosystems - Earth is Fighting Back!
1313
Earth4.5B years old
Life2B years old
Industrial Revolution; 11:59:59 on Dec 31
Humans150,000 years old
1800 1930 1960
1B
2B
3B
Population Growth Assaulting Ecosystems - Earth is Fighting Back!
1414
Earth4.5B years old
Life2B years old
Industrial Revolution; 11:59:59 on Dec 31
Humans150,000 years old
1800 1930 1960 2011
1B
2B
3B
7B
Population Growth Assaulting Ecosystems - Earth is Fighting Back!
1515
Earth4.5B years old
Life2B years old
Industrial Revolution; 11:59:59 on Dec 31
Humans150,000 years old
1800 1930 1960 2011
1B
2B
3B
7B
Population Growth Assaulting Ecosystems - World is Fighting Back!
4.5B years of stored fossil fuel Greenhouse gas = 400 vs. 250ppm
25k species go extinct/year 80 countries have no forest left
25 trucks of waste for 1 good 52k gallons of water per tree
1616
25+years ago
Genotype Phenotype codes for
ABCABC
XYZ
?But Today, Environmental Factors complicate the Phenotype
1717
ExposomeReactive electrophilesMetalsEndocrine disruptersImmune modulatorsReceptor-binding proteins
Science (2010)
Environment Linked to Explosion in NCDs
Diet
Drugs
Infections
Life-Style
Stress
Radiation
Pollution
Internal chemical environmentXenobioticsInflammation
Preexisting diseaseLipid peroxidationOxidative stress
Gut flora
Epigenetics
1818
The 69-year-old sun exposure as a trucker.
Condition known as photoaging is caused by the sun's UVA rays.
1919
Explosion in non-communicable disease (NCD):
Cancer kills ~8M / year will rise ~72% by 2030 T2 diabetes affects 346M will double by 2030 Autism affects 1/88 kids rose 57x in ~40y Upsurge in asthma, rhinitis, food allergies
Only 25% explained by genetics alone
Environmental factors have been implicated
Environment is Linked to Explosion of NCD Incidence
Science (2010)
Epigenetics is emerging as key link between environment & NCD
epidemic
2020
• Cancer is #1 cause of death in high-income countries
• Cancer will be major cause of death in every region
• Cancer will rise from 12.7M in 2008 to 22.2M by 2030
Take Away Goes Here
Global Cancer Cases Could Rise 75% by 2030
June 1, 2012
5 Most Commonly Diagnosed Cancer in 2008 (incidence per 100,000)
$$
*Very Highly Developed Countries $$$$
Highly Developed Countries $$$
Moderately Developed Countries $$
Under-Developed Countries $$
Men Women
Wealthiest are 15% of the world’s population BUT bear 40% of the cancer burden:
+ : SCREENING - : WESTERN LIFETYLE
2121
Breast Cancer – A Global Scourge
Global Incidence of Breast Cancer: 1,384,000 women diagnosed in 2008
Circulating Tumor Cells hold great promise !
Find & Measure CTCs DiagnosisPrognosisPrediction of Response1 in 1B
2222http://www.thedailybeast.com/newsweek/2011/08/14/some-medical-tests-procedures-do-more-harm-than-good.html
Are We Over-Testing / Treating?
2323
http://positivesideeffects.com/2011/07/09/medical-care-3rd-leading-cause-of-death/
Many “Advances” are Actually Harmful
2424
Only 25% of Cancer Drugs Work: $1 Trillion Wasted
25%
30%
47%
48%
57%
60%
60%
60%
62%
0% 10% 20% 30% 40% 50% 60% 70%
Cancer (all types)
Alzheimer disease
Hepatitis C
Osteoporosis
Diabetes
Asthma
Cardiac arrhythmias
Schizophrenia
Depression
Dual toxicity/efficacy challenge associated with the current drug-development model
Annual costs of approximately US$177B
Adverse drug reactions
4th leading cause of death
Toxicity Challenge
Efficacy rate with standard treatment
“If not for the great variability among individuals, medicine might have been a science and not an art.”
Sir William Osler (1849-1919)
2525
State of Health
Life Expectancy Declining
Cost of Healthcare Skyrocketing
Global Access Insufficient
Population Exploding
Earth Traumatized – Jeopardizing Sustainable Growth
Environmental Disease Factors are Accelerating
Many of today’s medicines are unsafe and ineffective
2626 Source: http://www.slideshare.net/jcanton/future-of-health-care-presentation
Emerging “Health” Market…
Healthier
Longer Lives
GenesSurrogate Markers
ProteomicsSNPs
Probabilityof Disease
PersonalizedMedical
Intervention
LifestyleModification
Enabling Personalized Health
EnvironmentalImpacts
2727 Revolutionizing Global Health
Agenda
1
2
State of Health
5
3
Disruptive Technology Enabling Personalized Health
Catalyzing a Bioeconomy
2828
Three Vectors that Enable Health
2929
INFORMATICS
GENOMIC ANALYSIS
Prevention
BIOTHERAPEUTICS
LIFE SCIENCES & TECHNOLOGY
Disruptive Tools to Revolutionize Health
IMAGING & PATHOLOGY
BIOMARKERS
TARGETED SMALLMOLECULE
CELLULAR SYSTEMS
3030
Need predictive tests (humanistic
models)
Biomarkers enabling
personalized detection and
therapy
Focus on Big Four - Cancer,
CVS, Stroke and Diabetes
Current industry trends:
99%+ attrition in pre-clinical
(adverse drug reactions)
$1B / 15 years
Small AnimalCellDNA, RNA Protein
HumanTissue
The Challenge Facing Our CustomersReverse the Decline in Drug Discovery Productivity
In Vitro In Vivo
3131
In Vitro In Vivo
Small AnimalCellDNA, RNA Protein
HumanTissue
The Challenge Facing Our CustomersReverse the Decline in Drug Discovery Productivity
3232
Pre-
Clin
ical
C
linic
alStrategic Goal
COST OF TESTING
DAT
A Q
UA
LITY
Revolutionary Technology: I-I-H Bridge
The Issue is the TissueHigh multiplexing
Automated tissue Dx platform
Accelerate pre-clinical imagingTranslational imaging probes
Multiplex DNA/RNAMore from less faster better
Dx and CDx
High content assaysStem cell capabilities
Clinical sequencing capabilities
in vitro to in vivo to human
LDT to IVD capabilityGlobal IVD and PMA
platformsQSR/ Dx kit manufacturing
Informatics systemsIntegrated informatics;
research & development to clinical trials
Small Animal
Cell
DNA, RNA Protein
Human
Tissue
3333
Automated Microfluidic Platforms for Enabling Genomics
Next Gen Sequencing
Informatics
Sample Prep Detection
Integrated Next Gen Sequencing Sample Prep
3434
Innovative Biomarkers & Imaging to Enable Translational Research
Arthritis
Integrin αvβ3
Inflammation
Renin
Oncology
Bone Biology
Hypertension
Cardiovascular
Physiologic
Cathepsin KHydroxyapatite
Vascular
Neutrophil Elastase
Gastric Emptying
Infectious disease Cathepsins B, L, SMMPs 2, 7, 9, 13
Hypoxia
Bacteria
FolateHer2/NeuAnnexin Liver Toxicology
Adaptation of
select serum
markers for in
situ imaging
From Bench to Clinic: I-I-H Bridge
3535
Traditional Pathology is “Prone to Error”
Improving Clinical Relevance* New York Times, Prone to Error: Earliest Steps to Find Cancer (2010)
90,000 Ductal Carcinoma in situ (D.C.I.S.) accumulated
cases misdiagnosed
Multiple biomarker classification
Do more with less faster and more precisely
60X
Circulating Tumor Cells
1 in 1B
3636
Multiplex Tumor Characterization
multiplexed
adeno.
squamous
others
ALK
ROS
MET
First application - lung cancer
• Shrinking Sample• Multiple Biomarkers • NGS
Synergistic Technologies Increase Clinical Accuracy
3737Source: millennium Predictive Medicine; Start-up 2000Source: http://www.slideshare.net/jcanton/future-of-health-care-presentation
“Driving Medicine Below the Symptom Line”
Predisposition Testing
Dis
ease
Pro
gres
sion
Screening
Diagnosis – Prognosis
Drug / Device Intervention
Post Treatment Testing
Healthy
Symptoms Appear
Three Vectors that Enable Health
3838
Lifestyle
Settings
Char
acte
ristic
s Environmental
PerkinElmer Health
Informatics
EnvironmentalDiagnostics
LST
3939 Revolutionizing Global Health
Agenda
1
2
State of Health
5
3
Disruptive Technology Enabling Personalized Health
Catalyzing a Bioeconomy
4040
The President’s Bioeconomy Blueprint – A Roadmap for the US
In April 2012, the White House unveiled a “Bioeconomy Blueprint” to harness
innovations in biological research to address national challenges in:
Health
Food
Energy
Environment
4141
New Fast-Growing Bio Markets
Molecular Diagnostics $15 Billion (by 2014, global)
Nanotechnology$1.6 Trillion (by 2015, global)
Metabolomics$864 Million (by 2018, global)
Food Safety(contaminants, pathogens, GMOs)
$4.6 Billion (by 2016, US alone)
4242
Strategic Objectives of the Bioeconomy Blueprint
Five Strategic Objectives :
1: Support R&D investments that will provide the foundation for the future US bioeconomy
2: Facilitate transition of bioinventions from research lab to markets (translation)
3: Reform regulations to reduce costs & increase speed , while protecting human & environmental health
4: Update training programs & align academic institutions incentives with student training for national workforce needs
5: Identify & support opportunities for public-private partnerships
ULTIMATE GOAL: Generate economic growth & address societal needsEXECUTION: Demands a skilled & innovative work force – a new generation of biotechnologists
4343
Bioeconomy Blueprint – Fostering the Right Workforce
The Bioeconomy Blueprint” highlights the critical roll of Community Colleges in
building American Skills:
Largest component of the Nation’s higher education system
Enroll >7.6M students
Work with businesses to create tailored programs that meet local economic needs
4444
Bioeconomy – Fostering the Right Attitude
Accelerate Disruptive Innovation
Implementation Vision
Culture - Leadership
360◦ Market Immersion
Strategic Roadmap
4545
Bringing technology, discovery, and development closer to patients
IRB re-invention
Bioeconomy Blueprint – Fostering Public-Private Partnerships
Government – Academia – Pharma – Med Inst Collaboration
4646
Personalized Health Innovation Center of Excellence
Located in Hopkinton, MassachusettsFully operational in late 2012350 jobs in Center of Excellence Will utilize “state of the art” innovation practices
4747
